2019
2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
Rathod S, McManus D, Rivera-Vinas J, Topal J, Martinello R. 2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime. Open Forum Infectious Diseases 2019, 6: s823-s824. PMCID: PMC6810941, DOI: 10.1093/ofid/ofz360.2063.Peer-Reviewed Original ResearchPiperacillin/tazobactamClostridioides difficile infectionMultivariate logistic regression modelCDI riskHealthcare-associated infectionsPTZ exposureLogistic regression modelsHospital admissionDifficile infectionΒ-lactam/β-lactamase inhibitorsCharlson Comorbidity Index scoreCommon healthcare-associated infectionsYale-New Haven HospitalComorbidity Index scoreAntibiotic stewardship effortsObservational cohort studyAntibiotic-associated diarrheaNew Haven HospitalFrequency of testingAnti-pseudomonal cephalosporinsCephalosporin therapyCohort studyΒ-lactamase inhibitorsAntibiotic therapySuppression therapy
2006
Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease
Martinello RA, Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease. Journal Of Infection 2006, 53: 248-254. PMID: 16412516, PMCID: PMC7112509, DOI: 10.1016/j.jinf.2005.11.010.Peer-Reviewed Original ResearchConceptsExacerbation of COPDChronic obstructive pulmonary diseaseObstructive pulmonary diseaseRespiratory syncytial virusHuman metapneumovirusPulmonary diseaseSyncytial virusObservational cohort studyRespiratory tract infectionsParainfluenza type 3Urban teaching hospitalCOPD patientsCohort studyTract infectionsParainfluenza 1HMPV genotypesRespiratory virusesNasopharyngeal specimensViral cultureEnrollment criteriaInfluenza ATeaching hospitalDirect immunofluorescenceExacerbationPatients